Trial reportClinical oral investigations2025
Three-session non-surgical therapy stabilizes microbiological and biochemical responses in patients with stage III/IV grade C periodontitis: a randomized clinical trial.
Trial report in Clinical oral investigations, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Adjunctive Gaseous Ozone Improves Clinical and Microbiological Outcomes in Periodontitis: A Randomized Split-Mouth Study.Dentistry journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesManagement of Stage III/IV Grade C periodontitis (SIII/IVGrC) remains challenging, and the optimal non-surgical approach has not been clearly established. This randomized controlled clinical trial aimed to compare the clinical, biochemical, and microbiological outcomes of single-session versus three-session non-surgical periodontal therapy in patients with SIII/IVGrC. MATERIALS AND
methodsThirty-three patients with SIII/IVGrC were randomly allocated to single-session (SSTG, n = 16) or three-session (TSTG, n = 17) therapy. Fifteen periodontally healthy individuals served as controls. Probing depth (PD), clinical attachment level (CAL), bleeding on probing (BOP), and plaque index (PI) were recorded at baseline and at 1, 3, and 6 months. The primary outcome was the change in probing depth, while secondary outcomes included changes in CAL, BOP, and selected microbiological and biochemical parameters. Gingival crevicular fluid (GCF) levels of IL-1β, IL-6, clusterin, cystatin C, and osteocalcin were quantified, and subgingival microbiota -including Porphyromonas gingivalis, Tannerella forsythia, Treponema denticola, and Aggregatibacter actinomycetemcomitans- were analyzed using checkerboard DNA-DNA hybridization.
resultsBoth treatment groups showed significant clinical improvements over 6 months (p < 0.05), with no intergroup differences in PD, CAL, BOP, or PI. At baseline, GCF IL-1β and cystatin C were elevated in SIII/IVGrC compared to controls (p < 0.05). TSTG achieved greater reductions in IL-1β (3 and 6 months) and cystatin C (3 months) and demonstrated more pronounced decreases in red and orange complex species than SSTG (p < 0.05).
conclusionsThree-session therapy provided superior biochemical and microbiological improvements compared with single-session therapy, indicating a more stabilizing effect on host-microbe interactions. CLINICAL RELEVANCE: For patients with SIII/IVGrC periodontitis, three-session therapy may offer enhanced modulation of inflammatory and microbial parameters while achieving comparable clinical outcomes to single-session therapy.
Indexed as
Identifiers
41449292What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.